Relapsed Myeloma: Navigating Post-BCMA Therapy Failure
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Relapsed Myeloma: Navigating Post-BCMA Therapy Failure
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies.
Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes.
Learning Objectives
- Understand mechanisms of resistance and progression following BCMA-targeted therapy.
- Explore non-BCMA treatment options, including alternative targets and novel agents.
- Recognize key factors influencing treatment selection and patient management.